Physician profile
Eli Allen
NPI 1164083192
$529.98
in general payments reported to CMS, 2019-2025
14 companies · $25.68 in 2025
The $25.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.50 · 2021: $66.11 · 2022: $182 · 2023: $240 · 2025: $25.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $140.30 | 2020-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.90 | 2021-2023 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $58.27 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $41.78 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.00 | 2021-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $28.17 | 2022 | |
| Lilly USA, LLC | $28.03 | 2022 | |
| Acadia Pharmaceuticals INC | $25.68 | 2025 | Nuplazid |
| Lundbeck LLC | $22.05 | 2022 | |
| Merck Sharp & Dohme LLC | $18.98 | 2022 | |
| Novo Nordisk INC | $15.79 | 2023 | |
| Amgen INC. | $15.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.57 | 2023 | Farxiga |
| Nestle Healthcare Nutrition INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.